Xeris Biopharma Holdings (XERS) Cash from Operations Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn | 37.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.53% |
| Mar 31, 2026 | 33.47% |
| Dec 31, 2025 | 48.03% |
| Sep 30, 2025 | 44.83% |
| Jun 30, 2025 | 26.18% |
| Mar 31, 2025 | 40.82% |
| Dec 31, 2024 | 27.41% |
| Sep 30, 2024 | 28.38% |
| Jun 30, 2024 | 19.75% |
| Mar 31, 2024 | 5.37% |
| Dec 31, 2023 | 39.03% |